Toxicities of targeted therapy and their management in kidney cancer.
about
Molecularly targeted drugs for metastatic colorectal cancerTherapy management of cardiovascular adverse events in the context of targeted therapy for metastatic renal cell carcinomaA Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, -2, and -3 tyrosine kinases in Chinese patients with advanced solid tumors.Tumoral cubilin is a predictive marker for treatment of renal cancer patients with sunitinib and sorafenibExtreme hypothyroidism associated with sunitinib treatment for metastatic renal cancerA review on various targeted anticancer therapies.Reversible posterior leukoencephalopathy syndrome induced by pazopanib.Evaluation of the impact of the cancer therapy everolimus on the central nervous system in miceCharacteristics of oral mucosal events related to bevacizumab treatment.Current status of targeted therapy for advanced renal cell carcinomaA large-scale prospective registration study of the safety and efficacy of sorafenib tosylate in unresectable or metastatic renal cell carcinoma in Japan: results of over 3200 consecutive cases in post-marketing all-patient surveillance.A randomised, phase II study of nintedanib or sunitinib in previously untreated patients with advanced renal cell cancer: 3-year results.The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.The use of targeted therapies in pancreatic neuroendocrine tumours: patient assessment, treatment administration, and management of adverse events.Buccodental side effects of sunitinib in patients with metastatic renal cell carcinomaMolecular subtyping of metastatic renal cell carcinoma: implications for targeted therapy.Sunitinib-induced hypothyroidism predicts progression-free survival in metastatic renal cell carcinoma patients.Role of cytoreductive nephrectomy in the era of targeted therapy for renal cell carcinoma.Tumor control versus adverse events with targeted anticancer therapies.Optimizing treatment for patients with metastatic renal cell carcinoma in the Central and Eastern European region.Antiangiogenic therapy for advanced renal cell carcinoma: management of treatment-related toxicities.Onychopathy induced by temsirolimus, a mammalian target of rapamycin inhibitor.Treating patients with metastatic renal carcinoma: an escape from Phase III.Neoadjuvant treatment in advanced renal cell carcinoma: current situation and future perspectives.Recent advances in the treatment of metastatic renal cell carcinoma.Dermatologic adverse events to targeted therapies in lower GI cancers: clinical presentation and management.Patient approach in advanced/metastatic renal cell carcinoma: focus on the elderly population and treatment-related toxicity.Drug-induced pneumonitis in cancer patients treated with mTOR inhibitors: management and insights into possible mechanisms.Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer.Targeting the mammalian target of rapamycin pathway with everolimus: implications for the management of metastatic breast cancer.Dermatological toxicity associated with targeted therapies in cancer: optimal management.Feasibility, efficacy and safety of tyrosine kinase inhibitor treatment in hemodialyzed patients with renal cell cancer: 10 years of experience.Development of chronic myeloid leukaemia in patients treated with anti-VEGF therapies for clear cell renal cell cancer.Appropriate management of cutaneous adverse events maximizes compliance with sorafenib treatment: a single-center experience.Effect of axitinib on the QT interval in healthy volunteers.Second-line treatment for renal cell cancer.Efficacy of a protocol including heparin ointment for treatment of multikinase inhibitor-induced hand-foot skin reactions.[Systemic treatment of metastatic renal cell carcinoma: change of paradigms after introduction of targeted therapy].Vitamin D derivatives potentiate the anticancer and anti-angiogenic activity of tyrosine kinase inhibitors in combination with cytostatic drugs in an A549 non-small cell lung cancer model.Tumoral ANXA1 Is a Predictive Marker for Sunitinib Treatment of Renal Cancer Patients.
P2860
Q26828735-8D9B886C-8A0E-4106-A142-C9652124D4A5Q27013665-B22B0651-CB2D-4409-AC13-2B3C59863BA2Q33433070-E7C258DF-D2E5-4BC4-A62A-160EB1F69C5AQ33665833-9109BD49-6E91-41A9-9C3A-29EC6322BF0BQ33760079-CF47C665-DF56-4541-B01B-4278B96533D4Q34164735-47915A6E-2155-4257-8605-9F8B543116A4Q34454240-E95C4BEF-7981-4BCD-A82D-CA4B6C9C2437Q34600979-A22803AC-04A7-4126-8198-3AD4B0BD5D1BQ35776273-5C40D69C-6492-4913-AD2A-1FB4A9221E52Q35903850-8300921E-A188-4BFD-A0AB-31E477354D50Q36137398-86F9CAB5-AE38-40A0-8315-FFFE8E4AEED9Q36287386-1FE5A2C0-51C1-420C-8F09-C9360779AF85Q36478715-9856B7E4-4090-4E7A-B58A-8D560BF0DAB3Q37117596-174B6462-3AF9-4450-9732-6D044A156E31Q37214287-A4D09D8B-F815-4925-8598-818D60FE61F6Q37623118-D23720AC-2814-4106-A957-0C0A6E5287BCQ37720982-7FDEFF28-BCD9-4347-928E-725A623B0E66Q37959320-DDDCE3E7-2385-41AD-A36F-8690F44368F9Q37969899-20127C05-6AC3-4AB8-9A6D-4268B546FA08Q37971055-2123494D-A85E-4FDE-BEA5-7369BB260206Q37983389-569BB948-11C4-4E8C-9C56-687276251FE6Q38012000-5A950EDF-4CE7-4B51-B98C-D32F90C97608Q38030592-E61F5848-623A-4A02-A704-E7EC88CDD826Q38068585-53A9D0F7-A197-4B25-B750-7AEA37AC2A38Q38108392-AC3D6D6C-F34F-46DD-B227-B02DF6FFB212Q38133409-5F425071-5A11-4E23-B810-E6FE35EE4055Q38155199-A484828A-B52D-485D-A5E8-98E851DF8CD4Q38187149-F279B6F3-4A96-49C0-9302-E4644B89F817Q38199328-D5545601-BFE7-4A82-A342-D204665016C4Q38223222-56CF167D-5B88-4247-9E2D-06BAE97B6B09Q38239381-E8A3F3CE-E97D-4EB5-A96D-0C9D0754E083Q38975599-11FB759A-9501-42CF-91D1-497D314DC812Q39172001-99FFE28D-50A4-4416-A578-BD38E1E81669Q39610498-B703209C-DF38-4F1A-B158-9C21502530CDQ41582221-7CE702CE-4068-4C89-B0FC-4123461A5D87Q42551794-66E5CA44-425B-42A3-9F02-86979AE8A6FDQ43785033-125E9CFC-58BA-459B-922C-7991E7AA5D59Q43810315-9AC4D5AC-C433-4451-923B-AA9E48CF17CAQ47107773-7F24F712-9FB7-4783-AC93-61BEEEDA97CBQ47108251-84C03E0D-9D68-4733-BD5E-26A1527E1098
P2860
Toxicities of targeted therapy and their management in kidney cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 14 January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Toxicities of targeted therapy and their management in kidney cancer.
@en
Toxicities of targeted therapy and their management in kidney cancer.
@nl
type
label
Toxicities of targeted therapy and their management in kidney cancer.
@en
Toxicities of targeted therapy and their management in kidney cancer.
@nl
prefLabel
Toxicities of targeted therapy and their management in kidney cancer.
@en
Toxicities of targeted therapy and their management in kidney cancer.
@nl
P2093
P50
P1433
P1476
Toxicities of targeted therapy and their management in kidney cancer
@en
P2093
Cora Sternberg
Francesco Montorsi
Giuseppe Di Lorenzo
Joaquim Bellmunt
Michael Staehler
P304
P356
10.1016/J.EURURO.2011.01.002
P407
P577
2011-01-14T00:00:00Z